AzTrials
AzTrials

AsthmaACT AANCT02671643

To Determine the Measurement Properties of the ACT in an African American Adolescent Population With Persistent Asthma

An observational study of Asthma, run by University of North Carolina, Chapel Hill at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Purpose: To determine the measurement properties of the asthma control test (ACT) in a prospective clinical study in an African American adolescent population. Read more about this study

Who is it for?
Ages 12 to 18 years
Conditions the study is for
Asthma
How many people
54 participants
Where
2 sitesUnited States
Study dates
Oct 2014to 1 Jun 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: 80 African-American adolescents ages 12-18 with a physician diagnosis of persistent asthma. These adolescents are followed at the UNC Asthma Clinic seen by either pediatric pulmonologists or allergists.

Who may be able to join

  • Self-identified as African-American
  • Ages 12-18 years
  • Live within convenient driving distance of the NC Children's Specialty Clinic in Raleigh, NC.
  • Physician-diagnosis of persistent asthma
  • Current treatment with appropriate therapy for persistent asthma symptoms as per the NHLBI guidelines including: Daily controller medication use for asthma requiring at least low-dose inhaled corticosteroids (ICS). Asthma may range from mild persistent through severe persistent asthma, to include subjects that may require daily or every other day oral corticosteroids for control of asthma symptoms

Who cannot join

  • Children younger than age 12 and older than 18
  • Children unable to perform spirometry
  • Medical history or underlying health problems that may preclude participation in the protocol per the study physician (including but not limited to cystic fibrosis, chronic bronchitis, recurrent pneumonia, immunodeficiency, hematologic disorders)
  • Subjects and families unwilling to travel to the clinic for the required 2 visits
  • Other uncontrolled health problems
  • Non-English speaking subjects

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • UNC Center for Environmental Medicine, Asthma and Lung Biology

    Chapel Hill, North Carolina, 27599

  • NC Children's Specialty Clinic, 4414 Lake Boone Trail, Suite 505

    Raleigh, North Carolina, 27607

Other trials in United States

About this study

Official title: To Determine the Measurement Properties of the ACT in an African American Adolescent Population With Persistent Asthma Followed at a Subspecialty Clinic

Purpose: To determine the measurement properties of the asthma control test (ACT) in a prospective clinical study in an African American adolescent population.

Read the detailed description

African Americans have a higher rate of asthma (11.2%) compared to whites (7.7%), according to the Centers for Disease Control and Prevention, and this asthma is disproportionally not well-controlled. African Americans have higher mortality from and healthcare utilization for their asthma. Their asthma severity is more likely to be underestimated by their "main asthma provider". African-American adolescents are at particularly high risk of asthma-related morbidity and mortality.

Because asthma control is now the focus of asthma care, assessment of control is the critical step in appropriate management. The two domains of asthma control, impairment and risk, evaluate the role asthma plays in a patient's quality of life and functional capacity on an ongoing basis and the risk their asthma presents for future adverse events. Although NAEPP guidelines contain a rubric for asthma control based on these domains, thus representing the "gold standard" for asthma care, their utilization may be time-consuming and cumbersome to implement in primary care offices, and primary care providers may be unfamiliar with their use. Minorities see subspecialists less often than Caucasians (28.3% vs 41%, p=0.001), and this difference could not be explained by age, gender, health insurance, education, employment, patient preference, or frequency of respiratory symptoms. For primary care practices following these patients, it remains imperative that the tools being used to gauge asthma control be evaluated and validated in this at-risk population.

At this time, there are approximately 17 questionnaires available for use in the assessment of asthma control, although most are not well validated. Of these, the most widely validated and most commonly used instrument is the Asthma Control Test (ACT). The ACT is a self-administered questionnaire intended to assess the impairment domain over the past four weeks and is completed by patients starting at age 12. The ACT has five questions with an overall best score of 25. For primarily adult Caucasian populations, the ACT has been found to be a valid, reliable, and responsive instrument of asthma control, and cut-offs for controlled and not well-controlled asthma (< 19) as well as minimal clinically important (MIC) differences (3 points) have been identified. However, measurement properties of the ACT are lacking in the African American adolescent asthma population. The landmark validation study for the ACT by Schatz et al was comprised of a large sample size of over 300 patients that showed that a cut-off score of 19 as distinguishing well-controlled versus not well-controlled asthmatics. However, the mean age was 35 for that study population, and concerns have been raised as to whether this cut-off is appropriate for adolescents in general. Moreover, concerns have been raised as to the application of these cut-offs for different ethnic populations. Recent studies examining the ACT in pediatric adolescent populations have found higher optimal cut points to distinguish control classifications; these groups included both European cohorts as well as children of Mexican descent in Southern California. The ACT has not been validated in a more ethnically diverse population such as in African American adolescents.

The measurement properties of validity, reliability, and responsiveness are critical to the usefulness of any questionnaire in both clinical and research settings. To date, we have been unable to identify a study that evaluated the measurement properties of the ACT in this at-risk minority population.

Lung function measures are included in the rubric of assessing asthma control by the NAEPP. Per these recommendations, spirometry should be available to physicians caring for asthma patients and used with initiation of treatment, change in asthma control, and every one to two years. While subspecialists often have access to spirometry, office-based spirometry is time-consuming, requires technical ability and staff training, equipment maintenance and calibration, and is not always available or feasible for use in primary care physician offices. Because spirometry may be of limited accessibility to primary care providers, questionnaires are quickly taking a leading role in asthma management. However, African Americans perceive asthma symptoms differently than Caucasians. They report less nighttime awakening and dyspnea, two symptoms that account for 20% of the ACT score, and children are less accurate describing their perceived asthma control. This type of under-reporting reflects a false level of asthma control when queried by the ACT and leads to inappropriate medical management when spirometry is not utilized.

Additionally, health literacy is often underestimated. In a review by Diette of approximately 500 mostly African American patients who were asked to read asthma information, only 27% were able to read at a high school level, the level at which most health information and instructions are written. Patients with limited health literacy and chronic illness know less about how to manage their disease and have a higher likelihood of poorly controlled disease and health status compared to their counterparts with higher health literacy. Due to this, the IOM identifies health literacy as being fundamental to quality care and also considers it a priority in health-care quality and disease prevention. Because currently used questionnaires are often provided to patients at the time of intake at a clinic visit for self-administration, a high level of health literacy in this minority adolescent population is a dangerous assumption that must be considered when addressing the utilization of tools in the assessment of asthma control by primary care providers and subspecialists alike.

As exploratory endpoints, we will obtain fractional exhaled nitric oxide (FeNO) measurements shortly after spirometry is performed. Elevated FeNO indicates eosinophilic airway inflammation and assists in assigning the correct asthma phenotype, which can have implications for asthma management. We will also obtain nasal epithelial lining fluid (ELF) for collection of nasal cytokines and chemokines. This information is useful for expanding our current understanding of the inflammatory mediators involved in asthma-associated airway inflammation.

Conditions
Asthma
Medical subject headings
Asthma

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cohen's kappa

    To determine the agreement of the ACT score at the standard cutpoint of >19 with physician assessment of control using Cohen's kappa.

    Measured: Baseline Visit

Secondary outcomes (1)
  1. Sensitivity of ACT Questionnaire

    A receiver-operating curve will be used to determine the best ACT cutpoint for assessment of control in this population. A logistic regression model will be used with 'control by physician' as the dependent variable and 'ACT score' as the independent variable. The model will include adjustment for repeated measures (baseline and 6 week visit).

    Measured: Six Weeks (Follow Up Visit)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Feb 2016 (estimated)
  2. Study startOct 2014
  3. Primary completion13 Apr 2017
  4. Study completion1 Jun 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
54 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02671643
Sponsor's protocol ID
14-1532
Acronym
ACT AA
Status last verified
Mar 2018
First submitted
28 Jan 2016
Last updated
23 Mar 2018
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Monzon ME, Manzanares D, Schmid N, Casalino-Matsuda SM, Forteza RM. Hyaluronidase expression and activity is regulated by pro-inflammatory cytokines in human airway epithelial cells. Am J Respir Cell Mol Biol. 2008 Sep;39(3):289-95. doi: 10.1165/rcmb.2007-0361OC. Epub 2008 Apr 3.

    PubMed 18390475
  • Krishnan JA, Diette GB, Skinner EA, Clark BD, Steinwachs D, Wu AW. Race and sex differences in consistency of care with national asthma guidelines in managed care organizations. Arch Intern Med. 2001 Jul 9;161(13):1660-8. doi: 10.1001/archinte.161.13.1660.

    PubMed 11434799
  • Zoratti EM, Havstad S, Rodriguez J, Robens-Paradise Y, Lafata JE, McCarthy B. Health service use by African Americans and Caucasians with asthma in a managed care setting. Am J Respir Crit Care Med. 1998 Aug;158(2):371-7. doi: 10.1164/ajrccm.158.2.9608039.

    PubMed 9700109
  • Cloutier MM, Schatz M, Castro M, Clark N, Kelly HW, Mangione-Smith R, Sheller J, Sorkness C, Stoloff S, Gergen P. Asthma outcomes: composite scores of asthma control. J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S24-33. doi: 10.1016/j.jaci.2011.12.980.

    PubMed 22386507
  • Juniper EF, Gruffydd-Jones K, Ward S, Svensson K. Asthma Control Questionnaire in children: validation, measurement properties, interpretation. Eur Respir J. 2010 Dec;36(6):1410-6. doi: 10.1183/09031936.00117509. Epub 2010 Jun 7.

    PubMed 20530041
  • Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999 Oct;14(4):902-7. doi: 10.1034/j.1399-3003.1999.14d29.x.

    PubMed 10573240
  • Korn S, Both J, Jung M, Hubner M, Taube C, Buhl R. Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. Ann Allergy Asthma Immunol. 2011 Dec;107(6):474-9. doi: 10.1016/j.anai.2011.09.001. Epub 2011 Oct 5.

    PubMed 22123375
  • Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, Kosinski M, Pendergraft TB, Jhingran P. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006 Mar;117(3):549-56. doi: 10.1016/j.jaci.2006.01.011.

    PubMed 16522452
  • Thomas M, Kay S, Pike J, Williams A, Rosenzweig JR, Hillyer EV, Price D. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J. 2009 Mar;18(1):41-9. doi: 10.4104/pcrj.2009.00010.

    PubMed 19240948
  • Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, Rosenzweig JC, Manjunath R. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol. 2007 Apr;119(4):817-25. doi: 10.1016/j.jaci.2006.12.662. Epub 2007 Mar 13.

    PubMed 17353040
  • Liu AH, Zeiger RS, Sorkness CA, Ostrom NK, Chipps BE, Rosa K, Watson ME, Kaplan MS, Meurer JR, Mahr TA, Blaiss MS, Piault-Louis E, McDonald J. The Childhood Asthma Control Test: retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthma. J Allergy Clin Immunol. 2010 Aug;126(2):267-73, 273.e1. doi: 10.1016/j.jaci.2010.05.031. Epub 2010 Jul 10.

    PubMed 20624640
  • Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005 May;99(5):553-8. doi: 10.1016/j.rmed.2004.10.008. Epub 2004 Nov 26.

    PubMed 15823451
  • Rhee H, Belyea MJ, Elward KS. Patterns of asthma control perception in adolescents: associations with psychosocial functioning. J Asthma. 2008 Sep;45(7):600-6. doi: 10.1080/02770900802126974.

    PubMed 18773334
  • Trochtenberg DS, BeLue R. Descriptors and perception of dyspnea in African-American asthmatics. J Asthma. 2007 Dec;44(10):811-5. doi: 10.1080/02770900701645769.

    PubMed 18097855
  • Trochtenberg DS, BeLue R, Piphus S, Washington N. Differing reports of asthma symptoms in African Americans and Caucasians. J Asthma. 2008 Mar;45(2):165-70. doi: 10.1080/02770900701847076.

    PubMed 18350410

Questions about this trial

What is this clinical trial studying?

An observational study of Asthma, run by University of North Carolina, Chapel Hill at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cohen's kappa (time frame: Baseline Visit). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02671643, which also lists 38 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in